EUCTR2012-000281-38-ES进行中（未招募）不适用
A Randomized, Controlled Study To Investigate The Efficacy, Safety And Pharmacokinetics Of Legalon® Sil, Alone Or In Combination With Ribavirin, For The Prevention Of Recurrent Hepatitis C In Liver Transplant Recipients
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Rottapharm
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed and dated informed consent before undergoing any trial-related procedures
- •2.Male or female patient aged between 18 and 70 years inclusive
- •3.Patient with documented HCV infection
- •4.Patient with a documented diagnosis of cirrhosis
- •5.Patient placed on waiting list for liver transplantation
- •6.Ability to communicate, participate, and comply with the requirements of the entire study [NB: patients that cannot afford the burden of daily visits to the center to receive the daily treatment before LT or patients with baseline characteristics (e.g. rare ABO and Rh blood groups) causing a low chance to receive a compatible graft within 42 days after randomization are eligible for the post-LT treatment only and can be randomized to Treatment Groups D or E].
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 140
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 16
排除标准
- •1.Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive)
- •2.Active septic infections at time of screening
- •3.Previous organ/tissue transplantation other than cornea and hair
- •4.Patients requiring combined transplantation
- •5.Use of systemic immunomodulators (including systemic corticosteroids) within 4 weeks of the screening visit or during the screening period
- •6.Total bilirubin value >10mg/dL [Patients with total bilirubin value >10mg/dL are eligible to receive the post-LT treatment only, and therefore will be randomized to Treatment Groups F or G]
- •7.Patients not eligible to be treated with ribavirin as per the instructions present in its prescribing information document
- •8.For females of childbearing potential:
- •-Pregnancy (i.e. positive pregnancy test at screening) or breast feeding
- •-Failure to agree to practice adequate contraception methods (e.g. oral contraceptives, intra-uterine device (IUD), transdermal contraceptive patch).
- •9.Male patients not vasectomized, who do not agree to abstain from intercourse or who do not use a condom
- •10.Treatment for HCV with any investigational medication (prior use of silymarin is not exclusionary)
- •11.Treatment for HCV with any licensed therapies or therapy with any interferon alpha within 30 days of the randomization visit
- •12.Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study
- •13.Any known pre-existing medical condition that could interfere with the listing of the patient or with his/her participation in and completion of the study, including but not limited to:
- •-Chronic pulmonary disease (e.g. clinical chronic obstructive pulmonary disease, interstitial lung disease, pulmonary fibrosis, sarcoidosis)
- •-Current or history of any clinically significant cardiac abnormalities/dysfunction (e.g. angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia) including current uncontrolled hypertension, or history of use of antianginal agents for cardiac conditions
- •14.Site personnel directly involved in the study or their family members
- •15.Known hypersensitivity to Legalon® SIL
研究者
相似试验
进行中（未招募）
1 期
A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major depressive disorder and bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.Schizophrenia, schizoaffective disorder, schizophreniform disorder, major depressive disorder or bipolar disorder type I and II (currently in a depressive episode)MedDRA version: 20.0Level: HLTClassification code: 10039620Term: Schizoaffective and schizophreniform disorders Class: 10037175MedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175MedDRA version: 20.0Level: PTClassification code: 10039626Term: Schizophrenia Class: 100000004873MedDRA version: 21.1Level: LLTClassification code: 10004936Term: Bipolar depression Class: 10037175CTIS2022-502185-24-00niversity Medical Center Utrecht1,254
进行中（未招募）
1 期
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for bipolar depression compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.Bipolar depressionMedDRA version: 21.1Level: LLTClassification code: 10004936Term: Bipolar depression Class: 10037175CTIS2023-506605-19-00niversitair Medisch Centrum Utrecht423
已完成
4 期
A study to investigate the real-life use of the Vannair SMART regime in adult asthma (the SMART study).AsthmaRespiratory - AsthmaACTRN12610000515099Medical Research Institute of New Zealand300
进行中（未招募）
1 期
A randomised, controlled trial to investigate the effect of a six-week intensified pharmacological treatment for major depressive disorder compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.Major depressive disorderMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175CTIS2023-506617-21-00niversitair Medisch Centrum Utrecht418
进行中（未招募）
4 期
A clinical study to investigate whether third-line treatments work better as a second-line treatment for people diagnosed with schizophreniaSchizophrenia, schizoaffective disorder or schizophreniform disorderMental and Behavioural DisordersISRCTN83479057niversity Medical Center Utrecht418